PROCEPT BioRobotics/$PRCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Ticker
$PRCT
Sector
Primary listing
Employees
756
Headquarters
Website
PRCT Metrics
BasicAdvanced
$1.9B
-
-$1.56
1.04
-
Price and volume
Market cap
$1.9B
Beta
1.04
52-week high
$96.70
52-week low
$32.11
Average daily volume
1.1M
Financial strength
Current ratio
9.212
Quick ratio
7.713
Long term debt to equity
20.039
Total debt to equity
20.572
Interest coverage (TTM)
-23.64%
Profitability
EBITDA (TTM)
-86.032
Gross margin (TTM)
64.19%
Net profit margin (TTM)
-30.60%
Operating margin (TTM)
-33.37%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-12.93%
Return on equity (TTM)
-26.40%
Valuation
Price to revenue (TTM)
6.879
Price to book
5.03
Price to tangible book (TTM)
5.05
Price to free cash flow (TTM)
-21.188
Free cash flow yield (TTM)
-4.72%
Free cash flow per share (TTM)
-1.651
Growth
Revenue change (TTM)
55.71%
Earnings per share change (TTM)
-24.35%
3-year revenue growth (CAGR)
76.87%
3-year earnings per share growth (CAGR)
-6.69%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Bulls say / Bears say
PROCEPT reported Q2 2025 revenue of $79.2 million, marking a 48% year-over-year increase and surpassing prior guidance by $2.5 million, underscoring strong procedural adoption. (Nasdaq)
Q2 gross margin expanded to 65%, up from 59% a year ago, driven by improved operational efficiencies and higher average selling prices, indicating scalable unit economics. (Nasdaq)
The appointment of medtech veteran Larry L. Wood as CEO effective September 2, 2025, brings over 40 years of leadership experience from Edwards Lifesciences, potentially enhancing strategic execution. (Investing.com)
The company recorded an adjusted EBITDA loss of $8.0 million in Q2 and forecasts a full-year EBITDA loss of $35.0 million, highlighting persistent profitability challenges. (Nasdaq)
Operating expenses climbed to $73.9 million in Q2, a 27% increase year-over-year driven by commercial and R&D investments, which may strain cash flow if revenue growth decelerates. (Nasdaq)
International revenue of $9.6 million in Q2 comprised just 12% of total sales, underscoring significant dependence on the U.S. market and limited global diversification. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $1.9B as of October 26, 2025.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of October 26, 2025.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.